Señales en vivo de ALLR | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	186 170
Volumen promedio	517 917
Capitalización de mercado	687 914
EPS	$0 ( 2024-03-08 )
Próxima fecha de ganancias	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.0150 (1.01%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-01	Benjamin Laura	Buy	0
2023-08-01	Vazzano Joseph Walter	Buy	0
2021-12-20	Carchedi Steve	Sell	70 477	Stock Options
2021-12-20	Carchedi Steve	Sell	156 025	Stock Options
2021-12-20	Carchedi Steve	Sell	252 555	Stock Options

INSIDER POWER
0.00
Last 5 transactions
Buy: 0 \| Sell: 505 299

Volumen Correlación

Largo: 0.21 (neutral)

Corto: -0.75 (moderate negative)

Signal:(51.57) Neutral

Allarity Therapeutics, Correlación

10 Correlaciones Más Positivas
JBLU	0.983
AKTS	0.982
FGEN	0.98
BIOL	0.979
NVCR	0.977
WOOF	0.976
SNPX	0.975
RIDE	0.974
HCSG	0.973
GSIT	0.973

10 Correlaciones Más Negativas
MSDA	-0.984
BRIVU	-0.984
NVCN	-0.973
BRIV	-0.972
SGII	-0.971
VLAT	-0.969
TIOA	-0.966
IXAQ	-0.963
TIOAU	-0.962
ALOR	-0.961

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Allarity Therapeutics, Correlación - Moneda/Commodity

-0.29
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.32
( neutral )

0.00
( neutral )

0.24
( neutral )

Allarity Therapeutics, Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-37 000.00 (0.00 %)
EPS:	$-119.56

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-37 000.00 (0.00 %)
EPS:	$-119.56

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-120 000 (0.00 %)
EPS:	$-2 359.71

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.630

Financial Reports:

No articles found.

Allarity Therapeutics,

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.